Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening
Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40%
November 5, 2026 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026.
For the three-month period ended September 30, 2026, as compared to the same period of 2025:
◦ Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58%
◦ Screening revenue of $67.6 million, an increase of 180%, and 83,000 Shield tests, an increase of 246%
• Generated non-GAAP gross margin of 67%, compared to 66% for the third quarter of 2025
• Received U.S. Food and Drug Administration (FDA) approval and CE-marking in Europe for Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant), the first FDA approval of a liquid biopsy companion diagnostic for longitudinal testing in breast cancer
• Received FDA approval for Guardant360 CDx as a companion diagnostic for INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib) for eligible patients with ESR1-mutated advanced or metastatic breast cancer
• Submitted a premarket approval (PMA) application to the FDA for Guardant360 Tissue • Launched Guardant Reveal Ultra with biopharma partners and remain on track for clinical launch in 2026 • Expanded commercial coverage for Shield to more than 80% of eligible lives, with key additions including UnitedHealth Group, Carelon Healthcare Services, and EviCore
• Successfully deployed the new FDA-approved lower COGS, higher-throughput Shield workflow
“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”
“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests,” said AmirAli Talasaz, co-founder and co-CEO. “Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.” 1
Revenue was $361.0 million for the third quarter of 2026, a 36% increase from $265.2 million for the corresponding prior year period. Oncology revenue grew 25% to $231.3 million for the third quarter of 2026, from $184.4 million for the corresponding prior year period, driven primarily by an increase in Oncology test volume, which grew 58% over the prior year period. Screening revenue grew 180% to $67.6 million for the third quarter of 2026, from $24.1 million for the corresponding prior year period, driven primarily by an increase in Shield test volume, which grew to 83,000 tests in the third quarter of 2026, from 24,000 tests in the prior year period. Biopharma & Data revenue grew 8% to $59.0 million for the third quarter of 2026, from $54.7 million for the corresponding prior year period. Licensing and other revenue was $3.1 million for the third quarter of 2026, compared to $2.0 million for the corresponding prior year period.
Gross profit, or total revenue less cost of revenue, was $236.2 million for the third quarter of 2026, an increase of $64.5 million or 38%, from $171.6 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 65% for the third quarter of 2026, as compared to 65% for the corresponding prior year period.
Non-GAAP gross profit was $240.2 million for the third quarter of 2026, an increase of $65.9 million or 38%, from $174.3 million for the corresponding prior year period. Non-GAAP gross margin was 67% for the third quarter of 2026, as compared to 66% for the corresponding prior year period.
Operating expenses were $368.9 million for the third quarter of 2026, as compared to $270.6 million for the corresponding prior year period. The year- over-year increase in operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support Screening and Oncology growth and an increase in stock-based compensation. Non-GAAP operating expenses were $287.4 million for the third quarter of 2026, as compared to $228.9 million for the corresponding prior year period. The year-over-year increase in non-GAAP operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support Screening and Oncology growth.
Net loss was $124.4 million for the third quarter of 2026, as compared to $92.7 million for the corresponding prior year period. Net loss per share was $0.93 for the third quarter of 2026, as compared to $0.74 for the corresponding prior year period.
Non-GAAP net loss was $38.8 million for the third quarter of 2026, as compared to $48.3 million for the corresponding prior year period. Non-GAAP net loss per share was $0.29 for the third quarter of 2026, as compared to $0.39 for the corresponding prior year period.
Adjusted EBITDA loss was $37.3 million for the third quarter of 2026, as compared to a $45.5 million loss for the corresponding prior year period.
Free cash flow for the third quarter of 2026 was $(37.2) million, as compared to $(45.8) million for the corresponding prior year period.
Cash, cash equivalents, and restricted cash were $1.1 billion as of September 30, 2026.
Guardant Health now expects full year 2026 revenue to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025. This compares to the prior range of $1.34 to $1.36 billion, representing growth of 36% to 38%.
• Oncology revenue is expected to grow approximately 30% and Oncology volume is now expected to grow over 50%.
• Biopharma & Data revenue growth is expected to be in the low double-digit range.
• Screening revenue is now expected to be in the range of $233 to $238 million, driven by Shield volume of 285,000 to 290,000 tests. This compares to the prior guidance of $218 to $230 million revenue and 270,000 to 285,000 tests.
Guardant Health now expects full year 2026 non-GAAP gross margin to be 65%, compared to prior guidance of 64% to 65%. The company expects total non-GAAP operating expenses to be in the range of $1.105 to $1.125 billion, an increase compared to the prior range of $1.080 to $1.100 billion. Guardant Health now expects full-year free cash flow burn of $205 million to $220 million, compared to the previous outlook of $195 million to $205 million.
Guardant Health will host a conference call to discuss the third quarter 2026 financial results after market close on Thursday, November 5, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event. 2
Guardant Health has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP loss from operations, non- GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA, and free cash flow.
We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax expense, amortization of intangible assets, impairment of non-marketable equity securities, gain on extinguishment of convertible notes, and other items, including contingent consideration and non-recurring legal expenses.
Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax expense; and other items, including contingent consideration and non-recurring legal expenses. Free cash flow is defined as net cash used in operating activities in the period less purchases of property and equipment in the period.
We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain items because we believe that these income and expenses do not reflect expected future operating performance. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.
These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 1,026,848 $ 378,203 Short-term marketable — 823,395 securities Accounts receivable, net 186,548 137,849 Inventory, net 93,490 85,876 Prepaid expenses and other current 36,519 40,723 assets Total current assets 1,343,405 1,466,046 Restricted cash 119,157 111,214 Property and equipment, net 151,474 145,915 Right-of-use assets 141,245 158,849 Intangible assets, net 24,988 25,921 Goodwill 77,257 77,257 Other assets, net 28,116 28,457 Total assets $ 1,885,642 $ 2,013,659 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable $ 102,512 $ 54,442 Accrued compensation 127,619 119,646 Accrued expenses 104,935 77,889 Deferred revenue 38,099 50,753 Total current liabilities 373,165 302,730 Convertible senior notes, 1,502,413 1,504,000 net Long-term operating lease 160,220 178,463 liabilities Other long-term liabilities 125,746 127,773 Total liabilities 2,161,544 2,112,966 Stockholders’ deficit: Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 134,719,874 and 130,635,301 shares 1 1 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively Additional paid-in capital 3,080,321 2,900,056 Accumulated other -5,133 -4,852 comprehensive loss Accumulated deficit -3,351,091 -2,994,512 Total stockholders’ deficit -275,902 -99,307 Total liabilities and stockholders’ $ 1,885,642 $ 2,013,659 deficit
Full text with the tables
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026
Revenue Guidance
Third quarter 2026 revenue growth of 36% driven by strong performance in
Oncology and Screening
Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of
38% to 40%
PALO ALTO, Calif.
November 5, 2026 – Guardant Health, Inc. (Nasdaq: GH), a leading precision
oncology company, today reported financial results for the quarter ended
September 30, 2026.
Third Quarter 2026 Financial Highlights
For the three-month period ended September 30, 2026, as compared to the same
period of 2025:
• Reported total revenue of $361.0 million, an increase of 36%, driven by:
◦ Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology
tests, an increase of 58%
◦ Biopharma & Data revenue of $59.0 million, an increase of 8%
◦ Screening revenue of $67.6 million, an increase of 180%, and 83,000 Shield
tests, an increase of 246%
• Generated non-GAAP gross margin of 67%, compared to 66% for the third quarter
of 2025
Recent Operating Highlights
• Received U.S. Food and Drug Administration (FDA) approval and CE-marking in
Europe for Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH
(camizestrant), the first FDA approval of a liquid biopsy companion diagnostic
for longitudinal testing in breast cancer
• Received FDA approval for Guardant360 CDx as a companion diagnostic for
INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib) for eligible
patients with ESR1-mutated advanced or metastatic breast cancer
• Submitted a premarket approval (PMA) application to the FDA for Guardant360
Tissue
• Launched Guardant Reveal Ultra with biopharma partners and remain on track for
clinical launch in 2026
• Expanded commercial coverage for Shield to more than 80% of eligible lives,
with key additions including UnitedHealth Group, Carelon Healthcare Services,
and EviCore
• Successfully deployed the new FDA-approved lower COGS, higher-throughput
Shield workflow
“Revenue grew 36% year over year as we continued to execute across Oncology,
Screening, and Biopharma,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology
volume grew 58% with broad contributions across our portfolio. The FDA approval
of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast
cancer patients, ushering in a new paradigm of cancer treatment. It reinforces
the role of Guardant360 in enabling earlier therapy decisions and strengthens
our leadership across the cancer care continuum.”
“Shield continued to build momentum in the third quarter, with volume more than
tripling year over year to 83,000 tests,” said AmirAli Talasaz, co-founder and
co-CEO. “Commercial coverage continues to expand, with recent policy updates
extending Shield coverage to approximately 100 million lives. With our lower
COGS, higher-throughput workflow now fully implemented, we have a strong
operational foundation to meet future Shield demand. Together, these advances
expand access to Shield and move us closer to making blood-based cancer
screening a routine part of preventive care.”
1
Third Quarter 2026 Financial Results
Revenue was $361.0 million for the third quarter of 2026, a 36% increase from
$265.2 million for the corresponding prior year period. Oncology revenue grew
25% to $231.3 million for the third quarter of 2026, from $184.4 million for the
corresponding prior year period, driven primarily by an increase in Oncology
test volume, which grew 58% over the prior year period. Screening revenue grew
180% to $67.6 million for the third quarter of 2026, from $24.1 million for the
corresponding prior year period, driven primarily by an increase in Shield test
volume, which grew to 83,000 tests in the third quarter of 2026, from 24,000
tests in the prior year period. Biopharma & Data revenue grew 8% to $59.0
million for the third quarter of 2026, from $54.7 million for the corresponding
prior year period. Licensing and other revenue was $3.1 million for the third
quarter of 2026, compared to $2.0 million for the corresponding prior year
period.
Gross profit, or total revenue less cost of revenue, was $236.2 million for the
third quarter of 2026, an increase of $64.5 million or 38%, from $171.6 million
for the corresponding prior year period. Gross margin, or gross profit divided
by total revenue, was 65% for the third quarter of 2026, as compared to 65% for
the corresponding prior year period.
Non-GAAP gross profit was $240.2 million for the third quarter of 2026, an
increase of $65.9 million or 38%, from $174.3 million for the corresponding
prior year period. Non-GAAP gross margin was 67% for the third quarter of 2026,
as compared to 66% for the corresponding prior year period.
Operating expenses were $368.9 million for the third quarter of 2026, as
compared to $270.6 million for the corresponding prior year period. The year-
over-year increase in operating expenses was primarily related to commercial
infrastructure expansion and marketing activities to support Screening and
Oncology growth and an increase in stock-based compensation. Non-GAAP operating
expenses were $287.4 million for the third quarter of 2026, as compared to
$228.9 million for the corresponding prior year period. The year-over-year
increase in non-GAAP operating expenses was primarily related to commercial
infrastructure expansion and marketing activities to support Screening and
Oncology growth.
Net loss was $124.4 million for the third quarter of 2026, as compared to $92.7
million for the corresponding prior year period. Net loss per share was $0.93
for the third quarter of 2026, as compared to $0.74 for the corresponding prior
year period.
Non-GAAP net loss was $38.8 million for the third quarter of 2026, as compared
to $48.3 million for the corresponding prior year period. Non-GAAP net loss per
share was $0.29 for the third quarter of 2026, as compared to $0.39 for the
corresponding prior year period.
Adjusted EBITDA loss was $37.3 million for the third quarter of 2026, as
compared to a $45.5 million loss for the corresponding prior year period.
Free cash flow for the third quarter of 2026 was $(37.2) million, as compared to
$(45.8) million for the corresponding prior year period.
Cash, cash equivalents, and restricted cash were $1.1 billion as of September
30, 2026.
2026 Guidance
Guardant Health now expects full year 2026 revenue to be in the range of $1.36
to $1.37 billion, representing growth of 38% to 40% compared to full year 2025.
This compares to the prior range of $1.34 to $1.36 billion, representing growth
of 36% to 38%.
Within this revenue range:
• Oncology revenue is expected to grow approximately 30% and Oncology volume is
now expected to grow over 50%.
• Biopharma & Data revenue growth is expected to be in the low double-digit
range.
• Screening revenue is now expected to be in the range of $233 to $238 million,
driven by Shield volume of 285,000 to 290,000 tests. This compares to the prior
guidance of $218 to $230 million revenue and 270,000 to 285,000 tests.
Guardant Health now expects full year 2026 non-GAAP gross margin to be 65%,
compared to prior guidance of 64% to 65%. The company expects total non-GAAP
operating expenses to be in the range of $1.105 to $1.125 billion, an increase
compared to the prior range of $1.080 to $1.100 billion. Guardant Health now
expects full-year free cash flow burn of $205 million to $220 million, compared
to the previous outlook of $195 million to $205 million.
Webcast Information
Guardant Health will host a conference call to discuss the third quarter 2026
financial results after market close on Thursday, November 5, 2026 at 1:30 pm
Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be
accessed at http://investors.guardanthealth.com. The webcast will be archived
and available for replay for at least 90 days after the event.
2
Non-GAAP Measures
Guardant Health has presented in this release certain financial information in
accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on
a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit,
non-GAAP research and development expense, non-GAAP sales and marketing expense,
non-GAAP general and administrative expense, non-GAAP loss from operations, non-
GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA,
and free cash flow.
We define our non-GAAP measures as the applicable GAAP measure adjusted for the
impacts of stock-based compensation and related employer payroll tax expense,
amortization of intangible assets, impairment of non-marketable equity
securities, gain on extinguishment of convertible notes, and other items,
including contingent consideration and non-recurring legal expenses.
Adjusted EBITDA is defined as net loss adjusted for interest income; interest
expense; other income (expense), net; provision for income taxes; depreciation
and amortization expense; stock-based compensation expense and related employer
payroll tax expense; and other items, including contingent consideration and
non-recurring legal expenses. Free cash flow is defined as net cash used in
operating activities in the period less purchases of property and equipment in
the period.
We believe that the exclusion of certain income and expenses in calculating
these non-GAAP financial measures can provide a useful measure for investors
when comparing our period-to-period core operating results, and when comparing
those same results to that published by our peers. We exclude certain items
because we believe that these income and expenses do not reflect expected future
operating performance. Additionally, certain items are inconsistent in amounts
and frequency, making it difficult to perform a meaningful evaluation of our
current or past operating performance. We use these non-GAAP financial measures
to evaluate ongoing operations, for internal planning and forecasting purposes,
and to manage our business.
These non-GAAP financial measures are not intended to be considered in isolation
from, as substitute for, or as superior to, the corresponding financial measures
prepared in accordance with GAAP. There are limitations inherent in non-GAAP
financial measures because they exclude charges and credits that are required to
be included in a GAAP presentation, and do not present the full measure of our
recorded costs against its revenue. In addition, our definition of the non-GAAP
financial measures may differ from non-GAAP measures used by other companies.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding
wellness and giving every person more time free from cancer. Founded in 2012,
Guardant is transforming patient care and accelerating new cancer therapies by
providing critical insights into what drives disease through its advanced blood
and tissue tests, real-world data and AI analytics. Guardant tests help improve
outcomes across all stages of care, including screening to find cancer early,
monitoring for recurrence in early-stage cancer, and treatment selection for
patients with advanced cancer. For more information, visit guardanthealth.com
and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of
federal securities laws, including statements regarding the potential utilities,
values, benefits and advantages of Guardant Health’s liquid biopsy tests or
assays, which involve risks and uncertainties that could cause the actual
results to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are based on
current expectations, forecasts and assumptions, and actual outcomes and results
could differ materially from these statements due to a number of factors. These
and additional risks and uncertainties that could affect Guardant Health’s
financial and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this press
release include those discussed under the captions “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operation” and elsewhere in its Annual Report on Form 10-K for the year ended
December 31, 2025, and in its other reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking statements in
this press release are based on information available to Guardant Health as of
the date hereof, and Guardant Health disclaims any obligation to update any
forward-looking statements provided to reflect any change in its expectations or
any change in events, conditions, or circumstances on which any such statement
is based, except as required by law. These forward-looking statements should not
be relied upon as representing Guardant Health’s views as of any date subsequent
to the date of this press release.
Investor Contact:
Zarak Khurshid
[email protected]
Media Contact:
Meaghan Smith
[email protected]
3
Guardant Health, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share data)
Three Nine
Months Months
Ended Ended
Septemb… Septem…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Reven… $ 360,975 $ 265,196 $ 997,618 $ 700,755
Costs
and
opera…
expen…
Cost
of 124,822 93,587 345,690 249,515
reven…
Resea…
and 100,838 89,957 288,409 265,927
devel…
expen…
Sales
and 177,218 127,375 536,304 351,279
marke…
expen…
Gener…
and 90,862 53,266 210,448 150,477
admin…
expen…
Total
costs
and 493,740 364,185 1,380,… 1,017,1…
opera…
expen…
Loss
from -132,765 -98,989 -383,2… -316,443
opera…
Inter… 9,749 7,391 31,099 24,063
income
Inter… -1,345 -943 -4,038 -2,717
expen…
Other
income 342 -48 493 7,778
(expe…
net
Loss
before
provi… -124,019 -92,589 -355,6… -287,319
for
income
taxes
Provi…
for 343 136 900 464
income
taxes
Net $ -124,362 $ -92,725 $ -356,5… $ -287,783
loss
Net
loss
per
share, $ -0.93 $ -0.74 $ -2.68 $ -2.32
basic
and
dilut…
Weigh…
shares
used
in
compu…
net 134,422 124,807 132,866 124,268
loss
per
share,
basic
and
dilut…
4
Guardant Health, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share data)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
Current assets:
Cash and cash equivalents $ 1,026,848 $ 378,203
Short-term marketable — 823,395
securities
Accounts receivable, net 186,548 137,849
Inventory, net 93,490 85,876
Prepaid expenses and other
current 36,519 40,723
assets
Total current assets 1,343,405 1,466,046
Restricted cash 119,157 111,214
Property and equipment, net 151,474 145,915
Right-of-use assets 141,245 158,849
Intangible assets, net 24,988 25,921
Goodwill 77,257 77,257
Other assets, net 28,116 28,457
Total assets $ 1,885,642 $ 2,013,659
LIABILITIES AND
STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable $ 102,512 $ 54,442
Accrued compensation 127,619 119,646
Accrued expenses 104,935 77,889
Deferred revenue 38,099 50,753
Total current liabilities 373,165 302,730
Convertible senior notes, 1,502,413 1,504,000
net
Long-term operating lease 160,220 178,463
liabilities
Other long-term liabilities 125,746 127,773
Total liabilities 2,161,544 2,112,966
Stockholders’ deficit:
Common stock, par value of
$0.00001 per
share; 350,000,000 shares
authorized;
134,719,874 and 130,635,301
shares 1 1
issued and outstanding as
of September
30, 2026 and December 31,
2025,
respectively
Additional paid-in capital 3,080,321 2,900,056
Accumulated other -5,133 -4,852
comprehensive loss
Accumulated deficit -3,351,091 -2,994,512
Total stockholders’ deficit -275,902 -99,307
Total liabilities and
stockholders’ $ 1,885,642 $ 2,013,659
deficit
5
Guardant Health, Inc.
Supplemental Revenue Information
(unaudited)
(in thousands)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Oncolo… $ 231,264 $ 184,402 $ 655,323 $ 493,646
Biopha…
and 58,972 54,731 172,896 156,127
data
Screen… 67,614 24,112 162,070 44,603
Licens…
and 3,125 1,951 7,329 6,379
other
Total $ 360,975 $ 265,196 $ 997,618 $ 700,755
revenue
Reconciliation of Selected GAAP Measures to Non-GAAP Measures
(unaudited)
(in thousands, except per share data)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
cost of $ 124,822 $ 93,587 $ 345,690 $ 249,515
revenue
Amorti…
of -151 -151 -449 -449
intang…
assets
Stock-…
compen…
expense
and
related -3,891 -2,564 -11,047 -7,713
employ…
payroll
tax
expense
Non-GA…
cost of $ 120,780 $ 90,872 $ 334,194 $ 241,353
revenue
GAAP
gross $ 236,153 $ 171,609 $ 651,928 $ 451,240
profit
Amorti…
of 151 151 449 449
intang…
assets
Stock-…
compen…
expense
and
related 3,891 2,564 11,047 7,713
employ…
payroll
tax
expense
Non-GA…
gross $ 240,195 $ 174,324 $ 663,424 $ 459,402
profit
GAAP
resear…
and $ 100,838 $ 89,957 $ 288,409 $ 265,927
develo…
expense
Stock-…
compen…
expense
and
related -15,896 -13,750 -46,370 -41,095
employ…
payroll
tax
expense
Other — -417 — -1,598
Non-GA…
resear…
and $ 84,942 $ 75,790 $ 242,039 $ 223,234
develo…
expense
GAAP
sales
and $ 177,218 $ 127,375 $ 536,304 $ 351,279
market…
expense
Stock-…
compen…
expense
and
related -18,230 -11,451 -50,526 -33,396
employ…
payroll
tax
expense
Non-GA…
sales
and $ 158,988 $ 115,924 $ 485,778 $ 317,883
market…
expense
GAAP
general
and $ 90,862 $ 53,266 $ 210,448 $ 150,477
admini…
expense
Amorti…
of -128 -236 -484 -834
intang…
assets
Stock-…
compen…
expense
and
related -28,291 -15,779 -72,642 -44,182
employ…
payroll
tax
expense
Other -19,000 -115 -21,400 -2,835
Non-GA…
general
and $ 43,443 $ 37,136 $ 115,922 $ 102,626
admini…
expense
6
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
loss $ -132,7… $ -98,989 $ -383,233 $ -316,4…
from
operat…
Amorti…
of 279 387 933 1,283
intang…
assets
Stock-…
compen…
expense
and
related 66,308 43,544 180,585 126,386
employ…
payroll
tax
expense
Other 19,000 532 21,400 4,433
Non-GA…
loss $ -47,178 $ -54,526 $ -180,315 $ -184,3…
from
operat…
GAAP
net $ -124,3… $ -92,725 $ -356,579 $ -287,7…
loss
Amorti…
of 279 387 933 1,283
intang…
assets
Stock-…
compen…
expense
and
related 66,308 43,544 180,585 126,386
employ…
payroll
tax
expense
Impair…
of
non-ma… — — — 5,000
equity
securi…
Gain on
exting…
of — — — -13,672
conver…
notes
Other 19,000 532 21,400 4,433
Non-GA…
net $ -38,775 $ -48,262 $ -153,661 $ -164,3…
loss
GAAP
net
loss
per $ -0.93 $ -0.74 $ -2.68 $ -2.32
share,
basic
and
diluted
Non-GA…
net
loss
per $ -0.29 $ -0.39 $ -1.16 $ -1.32
share,
basic
and
diluted
Weight…
shares
used in
comput…
GAAP
and
Non-GA… 134,422 124,807 132,866 124,268
net
loss
per
share,
basic
and
diluted
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(unaudited)
(in thousands)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
net $ -124,3… $ -92,725 $ -356,579 $ -287,7…
loss
Intere… -9,749 -7,391 -31,099 -24,063
income
Intere… 1,345 943 4,038 2,717
expense
Other
expense -342 48 -493 -7,778
(incom…
net
Provis…
for 343 136 900 464
income
taxes
Deprec…
and 10,178 9,408 29,181 29,686
amorti…
Stock-…
compen…
expense
and
related 66,308 43,544 180,585 126,386
employ…
payroll
tax
expense
Other 19,000 532 21,400 4,433
Adjust… $ -37,279 $ -45,505 $ -152,067 $ -155,9…
EBITDA
Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities
(unaudited)
(in thousands)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
used in $ -23,707 $ -35,413 $ -147,108 $ -158,3…
operat…
activi…
Purcha…
of
proper… -13,480 -10,350 -30,819 -20,458
and
equipm…
Free
cash $ -37,187 $ -45,763 $ -177,927 $ -178,8…
flow
7